Intravacc Secures French CIR Approval as Recognized Private Research Organization for 2025–2027

French biotech and pharmaceutical companies outsourcing vaccine R&D to Intravacc can now declare qualifying expenditures under the Crédit d'Impôt Recherche (CIR) framework, following the Dutch CDMO's recognition by the French Ministry of Higher Education, Research and Space as an approved private research organization for 2025, 2026, and 2027. The designation lowers a practical barrier that has historically complicated cross-border outsourcing arrangements for French sponsors managing R&D cost structures.

The CIR framework permits eligible R&D expenses, including work contracted to approved external organizations, to qualify for tax credit treatment under French fiscal rules. Intravacc's listed status means French partners can integrate outsourced vaccine development, analytical services, and cGMP clinical manufacturing into their CIR documentation without first establishing the CDMO's eligibility from scratch. Project-level eligibility remains subject to applicable CIR rules and any required assessment, so sponsors will still need precise project scoping and compliant invoicing to support their filings.

For QA directors and regulatory leads evaluating CDMO partnerships, the approval signals a level of institutional scrutiny that goes beyond standard commercial credentialing. Ministry recognition requires demonstration of genuine R&D capacity, covering antigen selection, process development, formulation, assay validation, and quality control, rather than manufacturing throughput alone. Intravacc's integrated offering spans viral, bacterial, conjugate, and E. coli-expressed protein vaccine platforms, with analytical capabilities that include immunological, biochemical, biophysical, cell-based, and analytical chemistry assays supporting identity, purity, structural characterization, and stability testing.

The approval also reflects a broader pattern of European governments formalizing recognition pathways for specialized CDMOs, a development with direct relevance for plant heads and outsourcing leads benchmarking partner qualification frameworks. Where a CDMO holds recognized status under a national R&D incentive scheme, the due-diligence burden on the sponsor shifts measurably, though it does not eliminate the need for robust technical and quality agreements aligned with ICH Q10 and applicable GMP expectations.

Intravacc has indicated it will support partners with project scoping and invoicing structures designed to align R&D activities with CIR documentation requirements, a commitment that will be tested as French partners begin filing against the 2025 approval period.

Source: GlobeNewswire via Intravacc press release, 27 May 2026.